{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=64", "query": { "condition": "Phase II", "page": 64 }, "page_size": 10 }, "pagination": { "page": 64, "page_size": 10, "total_count": 21412, "total_pages": 2142, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=65&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=63&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T23:51:32.519Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05355051", "title": "A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin's Lymphoma" ], "interventions": [ { "name": "Azacytidine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 24, "start_date": "2022-10-05", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-11-15T23:51:32.519Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05355051" }, { "nct_id": "NCT02560051", "title": "Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Estramustine", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 19, "start_date": "2015-11", "completion_date": "2017-09-14", "has_results": true, "last_update_posted_date": "2018-11-28", "last_synced_at": "2026-11-15T23:51:32.519Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02560051" }, { "nct_id": "NCT02250053", "title": "Exercise and Colon Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage II Colon Cancer", "Stage III Colon Cancer" ], "interventions": [ { "name": "Exercise", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2015-12", "completion_date": "2016-01-15", "has_results": false, "last_update_posted_date": "2020-04-09", "last_synced_at": "2026-11-15T23:51:32.519Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02250053" }, { "nct_id": "NCT05630937", "title": "Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable Hepatocellular Carcinoma (HCC)" ], "interventions": [ { "name": "NMS-01940153E", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nerviano Medical Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2020-11-13", "completion_date": "2024-08-06", "has_results": true, "last_update_posted_date": "2025-06-19", "last_synced_at": "2026-11-15T23:51:32.519Z", "location_count": 2, "location_summary": "Orange, California • St Louis, Missouri", "locations": [ { "city": "Orange", "state": "California" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05630937" }, { "nct_id": "NCT05519475", "title": "A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metabolic Dysfunction-Associated SteatoHepatitis (MASH)" ], "interventions": [ { "name": "ALN-HSD", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 120, "start_date": "2023-02-09", "completion_date": "2028-12-07", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T23:51:32.519Z", "location_count": 61, "location_summary": "Flagstaff, Arizona • Peoria, Arizona • Tucson, Arizona + 46 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05519475" }, { "nct_id": "NCT05799157", "title": "Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Verruca Vulgaris", "Warts", "Common Wart" ], "interventions": [ { "name": "VDMN-21 Patch Low Dose", "type": "DRUG" }, { "name": "VDMN-21 Patch High Dose", "type": "DRUG" }, { "name": "Vehicle Patch", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veradermics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "9 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "9 Years to 65 Years" }, "enrollment_count": 153, "start_date": "2023-02-28", "completion_date": "2025-02-25", "has_results": false, "last_update_posted_date": "2025-05-08", "last_synced_at": "2026-11-15T23:51:32.519Z", "location_count": 16, "location_summary": "Fort Smith, Arkansas • San Diego, California • Plainfield, Indiana + 13 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Plainfield", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05799157" }, { "nct_id": "NCT00291057", "title": "Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lice Infestations" ], "interventions": [ { "name": "MALG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "24 Months", "sex": "ALL", "summary": "6 Months to 24 Months" }, "enrollment_count": 30, "start_date": "2006-02", "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2013-12-23", "last_synced_at": "2026-11-15T23:51:32.519Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • St. Petersburg, Florida • West Palm Beach, Florida + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Miamiville", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00291057" }, { "nct_id": "NCT03606967", "title": "Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Invasive Breast Carcinoma", "Metastatic Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Personalized Synthetic Long Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Sacituzumab Govitecan", "type": "BIOLOGICAL" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2021-04-13", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T23:51:32.519Z", "location_count": 30, "location_summary": "Orange, California • Sacramento, California • Aurora, Colorado + 22 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03606967" }, { "nct_id": "NCT05116800", "title": "Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Soft Tissue Sarcoma", "Undifferentiated Pleomorphic Sarcoma", "Myxofibrosarcoma", "Leiomyosarcoma", "Liposarcoma", "Angiosarcoma", "Synovial Sarcoma", "Rhabdomyosarcoma", "Spindle Cell Sarcoma", "High Grade Sarcoma", "Bone Sarcoma", "Osteosarcoma", "Ewing Sarcoma of Bone" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "9-ING-41", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 0, "start_date": "2022-03-01", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2021-12-07", "last_synced_at": "2026-11-15T23:51:32.519Z", "location_count": 2, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT05116800" }, { "nct_id": "NCT05903092", "title": "MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "SCLC", "Extensive Stage Small Cell Lung Cancer", "Limited Stage Small-Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Monalizumab", "type": "DRUG" }, { "name": "Carboplatin or Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Khalil Choucair", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2023-09-26", "completion_date": "2030-10-31", "has_results": false, "last_update_posted_date": "2026-11-05", "last_synced_at": "2026-11-15T23:51:32.519Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Iowa City, Iowa • Detroit, Michigan + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05903092" } ] }